37.14 -0.19 (-0.51%)
After hours: 5:52PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||37.12 - 37.33|
|52-week range||32.32 - 39.43|
|PE ratio (TTM)||10.37|
|Earnings date||31 Jul 2018|
|Forward dividend & yield||1.36 (3.66%)|
|1y target est||39.80|
Wednesday, July 18: Novartis says it will follow Pfizer in delaying planned price hikes after pressure from Trump; US government paid $77,000 to President Donald Trump’s Turnberry golf resort in Scotland before he stayed there; Papa John Schnatter says he regrets resigning as chairman of Papa John’s and is fighting back against the board. Yahoo Finance’s Dan Roberts serves up the news of the day -- on his birthday!
Johnson & Johnson (JNJ) announced its Q2 2018 earnings results on July 17. JNJ stock rose ~3.5% on the day and ended at a closing price of $129.12. On July 16, the stock closed at $124.69.
Returns for the firm’s largest fund, Jensen Quality Growth (JENSX), continue to top the S&P 500, including over the past 10 years through June 30. Other large second-quarter moves include taking large cuts to positions in Nike (NKE) and Mastercard (MA), and trimming back in Coca-Cola (KO) and Microsoft (MSFT). Jensen hasn’t yet responded to a request for comment.
Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.
Allergan’s stock price has fallen nearly 28.4% over the last 12 months, but it’s risen ~7.5% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~17.7% over the next 12 months.
Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.
There have been over 50 component changes to the Dow's since 1896, and these three stocks could be the next to join the prestigious index.
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
Celgene’s (CELG) Abraxane reported revenue of $262 million in the first quarter, reflecting an ~11.0% YoY (year-over-year) rise. Abraxane’s sales grew 12.0% in the US market to reach $159.0 million. In the international market, its sales grew 9.6% to reach $103 million. Otezla and other drugs’ revenue trends
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.
Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.
Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
The drugmaker's second reorganization in four years signals where the company is headed. But it doesn't solve its most serious problem.
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.
When Ian Read decided to hoist the price of 100 products earlier this month, the Pfizer chief executive was unprepared for the fallout. Shortly after, he received a telephone call from Alex Azar, the health secretary, who warned him the President was not bluffing. “Alex conveyed that Mr Trump was very angry with Pfizer,” said one person briefed on the call.
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Less than 48 hours after Donald Trump took to Twitter to say the company “should be ashamed” of raising prices on 100 products, the drugmaker demurred and said it would defer the increases. also followed a series of thinly veiled warnings from Alex Azar, the health secretary, who said its decision to raise prices this month would “be remembered for creating a tipping point in US drug pricing policy”. The company said it would defer the increases until the end of the year or until Mr Trump implements his “blueprint to strengthen the healthcare system” — a complex string of measures announced in May, aimed at lowering drug prices.